QDEL
21.01
-1.5%↓
NERV
4.3
+5.91%↑
LSTA.US
2.02
-4.72%↓
QDEL
21.01
-1.5%↓
NERV
4.3
+5.91%↑
LSTA.US
2.02
-4.72%↓
QDEL
21.01
-1.5%↓
NERV
4.3
+5.91%↑
LSTA.US
2.02
-4.72%↓
QDEL
21.01
-1.5%↓
NERV
4.3
+5.91%↑
LSTA.US
2.02
-4.72%↓
QDEL
21.01
-1.5%↓
NERV
4.3
+5.91%↑
LSTA.US
2.02
-4.72%↓
24h
Current
Min
111.9
Max
116.05
Income | -83M 652M |
|---|---|
Sales | -25M 5.3B |
EPS | 2.07 |
Dividend yield | 1.34 |
Profit margin | 12.407 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +17.72% upside |
Dividend yield Sector Avg | 1.34% 2.37% |
|---|
Market Cap | 98B |
|---|---|
Previous open | 114.85 |
Previous close | 111.9 |
By Acuity
24%
76%
55 / 374 Ranking in Healthcare
By Trading Central
Confidence
Strong Bearish Evidence
121.15 / 123.55 Support & Resistance
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
13 lis 2025, 13:40 UTC
Germany's Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results -- Update
DJ
Read
13 lis 2025, 06:24 UTC
Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units
DJ
Read
1 paź 2025, 08:54 UTC
Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site
DJ
Read
13 lis 2025, 07:57 UTC
Germany's Merck KGaA Beats Expectations With Strong Results -- Market Talk
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Sees 2025 Ebitda Before Exceptional Items at EUR6B-EUR6.2B
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Narrows 2025 View To Sales EUR20.8B-EUR21.4B
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Sees 2025 Organic Ebitda Before Exceptional Items Growth of 5%-7%
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Had Guided for 2025 Organic Sales Growth of 2% to 5%
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Says Guidance Midpoint Remains Unchanged
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Had Guided for 2025 Organic Ebitda Before Exceptional Items Growth of 4%-8%
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Sees 2025 Organic Sales Growth of Around 3%
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA 3Q After-Tax Profit EUR898M
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA: 3Q Net Sales Rose 5.2% Organically With Solid Growth Across Sectors
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA Narrows 2025 View
DJ
Read
13 lis 2025, 06:00 UTC
Analysts Saw Merck KGaA 3Q Net Sales at EUR5.23B
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA 3Q Ebitda Before Exceptional Items EUR1.67B
DJ
Read
13 lis 2025, 06:00 UTC
Analysts Saw Merck KGaA 3Q Ebitda Before Exceptional Items EUR1.56B
DJ
Read
13 lis 2025, 06:00 UTC
Merck KGaA 3Q Sales EUR5.32B
DJ
Read
6 lis 2025, 21:52 UTC
Universal Display: Portfolio Includes More Than 300 Issued and Pending Patents Worldwide, Covering More Than 110 Unique Patent Families >OLED
DJ
Read
6 lis 2025, 21:51 UTC
Universal Display Corp to Acquire Emissive OLED Patent Assets From Merck KGaA, Darmstadt, Germany
DJ
Read
16 paź 2025, 08:34 UTC
Merck KGaA's Cost Cutting Likely Led to Profitability Target Raise -- Market Talk
DJ
Read
15 paź 2025, 12:08 UTC
Merck KGaA Didn't Disclose Financial Details
DJ
Read
15 paź 2025, 12:07 UTC
Merck KGaA: JSR's Amsphere Protein A Resin Tech Complements Existing Biologics Portfolio
DJ
Read
15 paź 2025, 12:07 UTC
Merck KGaA: Unit is Based in Belgium, Has 50+ Employees
DJ
Read
15 paź 2025, 12:06 UTC
Merck KGaA: Deal Will Strengthen Position in Bioprocessing Market
DJ
Read
15 paź 2025, 12:05 UTC
Merck KGaA: Definitive Agreement Signed Today
DJ
Read
15 paź 2025, 12:05 UTC
Merck KGaA: Transaction Expected to Close by End of 2Q 2026
DJ
Read
15 paź 2025, 12:04 UTC
Merck KGaA to Buy Chromatography Business JSR Life Sciences
DJ
Read
15 paź 2025, 12:03 UTC
Merck KGaA to Buy Chromatography Business of JSR Life Sciences
DJ
Read
7 sie 2025, 08:04 UTC
Germany's Merck Misses Expectations on Weaker Electronics Performance -- Market Talk
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 138.38 EUR 17.72%
High 182 EUR
Low 105 EUR
Based on 9 Wall Street analysts offering 12 month price targets forMerck KGaA - Dist in the last 3 months.
By TipRanks
Buy
9 ratings
5
Buy
3
Hold
1
Sell
Based on 9 analysts giving stock ratings to Merck KGaA - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Neutral Evidence
The bullish and bearish events are balanced.
Long Term
Bearish Evidence
All events are bearish.
By Acuity
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$